Key result
NSAIDs plus colchicine remain the cornerstone of pericarditis treatment while IL-1 blockers reduce recurrence.
This review reinforces the use of NSAIDs and colchicine as first-line therapies for pericarditis, reserving glucocorticoids for specific cases and highlighting IL-1 blockers for recurrent, refractory disease.
Answers are grounded in this paper and cite their sources.
First-line NSAIDs plus colchicine remain standard for pericarditis with IL-1 blockers for recurrent cases; reinforces consensus and extends applicability to refractory disease.
Pericarditis is an inflammatory disease that affects the pericardial sac surrounding the heart. Although usually benign, recurrence is a common complication, and pericarditis may lead to cardiac tamponade or constrictive pericarditis. Non-steroidal anti-inflammatory drugs, with adjunctive colchicine, are the cornerstone of pericarditis treatment. Glucocorticoids should be used with caution. Interleukin-1 blockers anakinra and rilonacept have demonstrated efficacy in reducing pericarditis recurrence rates. Ongoing trials with alternative treatments (e.g. goflikicept, cannabidiol) are showing promise, and new treatment options should be supported by further investigation of pericarditis pathophysiology.
No takes yet. Share an insight, caveat, or question.
Aisling McGuigan (2026) conducted a review in Acute and recurrent pericarditis. NSAIDs, colchicine, and interleukin-1 blockers was evaluated. Non-steroidal anti-inflammatory drugs with adjunctive colchicine are the cornerstone of pericarditis treatment, while interleukin-1 blockers demonstrate efficacy in reducing recurrence rates.
Synapse has enriched 10 related papers. Consider them for comparative context: